BTK inhibitors (BTKis) are new drugs in B cell lymphoma, which have been used in newly diagnosed relapse/refractory (R/R) or rituximab-resistant DLBCL [36]. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.